Trial Details

Recruiting
Basic Information
Clinical ID c5031
Identifier IRCT20220409054467N3
Trial Title Effects of Adalimumab in Iranian Pediatric with Inflammatory Bowel Disease
Trial URL Visit Original Page
Study Information
Study Results

NULL

Conditions Inflammatory bowel disease. Inflammatory polyps of colon with intestinal obstruction;K51.412
Interventions Intervention group: Administration of adalimumab (40 mg/0.8 ml) which is injected in patients weighing less than 40 kg based on the following dose: 80 mg first, 40 mg two weeks later, 20 mg two weeks after the second dose and then depending on the respons
Participant Information
Sponsor Tehran University of Medical Sciences
City NULL
Country/Region Iran
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, CHILD, TEENAGER
Study Design
Study Type interventional
Phase NULL
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL